SLC22A2 and in situ carcinoma: Hence, this is the first study to comprehensively evaluate the impact of OCT2 inhibition or cimetidine on the in vitro anticancer effects of CIS across multiple concentrations and time points, and to systemically examine their nature of interactions at static concentrations and over a time-course using multiple modeling approaches in OCT2 expressing and non-expressing cancer cell lines.